Skip to content

Definium Therapeutics, Inc.

American clinical-stage biopharmaceutical company developing psychedelic-based treatments

DFTX Nasdaq SEC CIK 1813814

Follow Definium Therapeutics Weekly email: filings, results, news

News

12 stories filed under Definium Therapeutics, grouped into ongoing threads

Discusses phase

Thread · 3 stories

Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript

Markets 19 d ago also on III

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder - Slideshow

Markets 42 d ago

Definium Therapeutics stock jumps 20% on Phase 3 trial results

Markets 43 d ago

More coverage

Definium Therapeutics CEO Robert Barrow sells $721,732 in shares

Markets 19 d ago 3 sources

Definium Therapeutics Announces New Employee Inducement Grants

Markets 24 d ago

Stifel confident in Definium Therapeutics stock after management dinner

Markets 24 d ago

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Markets 29 d ago

Definium Therapeutics Announces New Employee Inducement Grants

Markets 38 d ago

Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst

Markets 43 d ago

STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial

Markets 43 d ago

Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript

Earnings 48 d ago

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Markets 49 d ago

Profile

Headquarters: NEW YORK, NY, United States
Sector: Healthcare
Industry: Medicinal Chemicals & Botanical Products
Website: definiumtx.com

Peers

Where this page comes from

Profile · SEC EDGAR, Wikidata

News · 12 stories clustered from the RSS aggregator